Indications And Dose
Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs ▶BY MOUTH ▶Adult: 100 mg twice daily for 24 weeks, continue appropriate combination therapy after delamanid
PDF page 641
Loading InternPractice…
Drug reference
Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs ▶BY MOUTH ▶Adult: 100 mg twice daily for 24 weeks, continue appropriate combination therapy after delamanid
PDF page 641
QTc interval more than 500 milliseconds (derived using Fridericia’s formula). serum albumin less than 28 g/litre
PDF page 641
Risk factors for QT interval prolongation (e.g. electrolyte disturbances, acute myocardial infarction, heart failure with reduced left ventricular ejection fraction, severe hypertension, left ventricular hypertrophy, bradycardia, congenital long QT syndrome, history of symptomatic arrhythmias)
PDF page 641
→Appendix 1: delamanid
PDF page 641
▶Common or very common Anxiety. appetite decreased. asthenia. chest pain. cough. depression. dyslipidaemia. dyspnoea. ear pain. electrolyte imbalance. gastrointestinal discomfort. haemoptysis. headache. hyperhidrosis. hypertension. hypotension. malaise. muscle weakness. nausea. oropharyngeal pain. osteochondrosis. pain. palpitations. peripheral neuropathy. photophobia. psychotic disorder. QT interval prolongation. reticulocytosis. sensation abnormal. skin reactions. sleep disorders. throat irritation. tinnitus. tremor. vomiting ▶Uncommon Aggression. atrioventricular block. balance impaired. dehydration. delusional disorder, persecutory type. dysphagia. extrasystole. hepatic function abnormal . increased risk of infection. lethargy. leucopenia. oral paraesthesia. psychiatric disorders. thrombocytopenia. urinary disorders Infection
PDF pages 641, 642
Effective contraception required during treatment.
PDF page 642
Manufacturer advises avoid—toxicity in animal studies.
PDF page 642
Manufacturer advises avoid—present in milk in animal studies.
PDF page 642
Manufacturer advises avoid in moderate to severe impairment.
PDF page 642
Manufacturer advises avoid in severe impairment—no information available.
PDF page 642
▶Monitor serum albumin and electrolytes before starting treatment and then during treatment—discontinue treatment if serum albumin less than 28 g/litre. ▶Obtain ECG before starting treatment and then monthly during treatment (more frequently if serum albumin 28–34 g/litre, or if concomitant use of potent CYP3A4 inhibitors, or if risk factors for QT interval prolongation, or if QTc interval 450–500 milliseconds in men or 470–500 milliseconds in women)—discontinue treatment if QTc interval more than 500 milliseconds (derived using Fridericia’s formula). l HANDLING AND STORAGE Dispense in original container (contains desiccant).
PDF page 642
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 8, 21 ▶Deltyba (Otsuka Novel Products GmbH) A Delamanid 50 mg Deltyba 50mg tablets | 48 tablet P £1,250.00
PDF page 642
100 mg twice daily for 24 weeks, continue
First-line fragment. Read the complete Indications and Dose section above.
PDF page 641